Involving the Community in Randomised Microbicide Clinical Trials: Lessons from 6 MDP African Clinical Trial Sites So Far Richard I. Mutemwa CAR/S3RI.

Slides:



Advertisements
Similar presentations
Group 1.3 Relationships between RECs in multi-centre, international studies –problems and solutions.
Advertisements

MTV Staying Alive Ignite A Pilot Project. About MTV Staying Alive // Global: MTV is a global media and general entertainment company with young people.
Medication Reconciliation in Home & Community Care Jo Dunderdale, RN, MA Program Development & Planning Leader Home & Community Care Vancouver Island Health.
Global Prevention Research Advocacy Partnerships Good Participatory Practice Initiative In November 2007, UNAIDS and AVAC published Good Participatory.
Vocational Rehabilitation QUEST BRAIN INJURY SERVICES Fleur Colohan Vocational Instructor Elaine Armstrong Head of Brain Injury Services.
1 GROUPWORK (1) Ethical/ Behavioural Group Rotational brainstorming problem analysis Consultation on ethical-legal complexities in adolescent HIV vaccine.
Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
New Prevention Technologies Workshop Module 3: Overview of Prevention Research
Contraceptive use and uptake Hasinah Asmal, Samantha Govender, Ian Naicker, Dinesh Singh, Gita Ramjee.
HIV Clinical Trials Janice Price, M.Ed, RN HIV Clinical Research Program Coordinator Swedish Medical Center Seattle, WA USA.
Presenter Instructions This slide presentation is designed to assist you with your education efforts about clinical trials. Each slide includes a note.
Forming and Sustaining Community Groups / Community Advisory boards (CWGs/CABs) Presenter: Smangaliso Ntshele Community Mobilization Project Leader, Medical.
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
“Talk to Your Doc”: an outreach by medical students to high school students Angela Towle & William Godolphin Division of Health Care Communication & Faculty.
First Hand Perspective of working on a Microbicides Phase111 Trial Misiwe Mzimela: Social Science Coordinator at Africa Centre.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Promoting Rational Drug Use in the Community Developing a country plan.
Communication for Behaviour and Social Change Making a difference through communication!
Community Issues And Needs Associated With Microbicides Clinical Trials Presenter: John M. Mutsambi, Community Liaison Officer with University of Zimbabwe.
Personalisation – what does it mean ? Levers for Change event 1 st May 2009.
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
Community Engagement in clinical trials Projet Ubuzima experience By Marie Michèle UMULISA Community Outreach & Recruitment Manager, Projet Ubuzima.
Priority setting in Ontario's LHINs: Ethics & economics in action Jennifer Gibson, PhD University of Toronto Joint Centre for Bioethics Craig Mitton, PhD.
What Makes a Successful Trial? MorenikeUkpong Nigeria HIV Vaccine and Microbicide Advocacy Group.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Good Participatory Practice UNAIDS & AVAC Document Pauline Irungu Global Campaign for Microbicides.
MDP301 An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5.
Overview of the Plain Talk Data Collection System Sarabeth Shreffler, MPH, CHES Program Officer, Plain Talk Program Public/Private Ventures.
© The Association for Dementia Studies Mixed methods evaluation of the Intergenerational Schools Dementia Project The challenges of working with children.
Introduction to Research Ethics Africa RWG Workshop 21 May 2003 Stella Kirkendale Wayne Wilson.
Nursing Research Capacity Building. Background CON –opened as 9 th College at SQU in 2008 The CON’s next challenge is promoting nursing care based on.
Background Study Objectives Poster No. B50 Track 2  Family planning affects women’s health and lives, and depends on a variety of socio-demographic and.
1 Chan Troi Moi Centers Phase II Campaign. 2 VCT Social Marketing Strategy Increase knowledge of and demand for VCT services by select target groups Increased.
Mixed methods in medical research Robert Pool Centre for International Health, Hospital Clinic, University of Barcelona London School of Hygiene & Tropical.
COMMUNITY CONSULTATION: LESSONS LEARNED IN HIV COMMUNITY-BASED RESEARCH Ronald P. Strauss, D.M.D., Ph.D. University of North Carolina at Chapel Hill.
CONDUCTING A PUBLIC OUTREACH CAMPAIGN IMPLEMENTING LEAPS IN CENTRAL AND EASTERN EUROPE: TRAINERS’ HANDBOOK Conducting a Public Outreach Campaign.
Children and Young Peoples’ Participation. Increasingly recognised as a mark of a quality service Belief that this is how ‘transformational change’ can.
Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.
Evaluation Workshop Self evaluation – some workable ideas and approaches.
Path Risks, Benefits and Inducements Finding the Balance.
 The underrepresentation of diverse populations in research an important barrier to: ◦ Understanding differences between groups ◦ Developing culturally.
Overview of Microbicide Trials Issues and Challenges.
Program Evaluation Dr. Ruth Buzi Mrs. Nettie Johnson Baylor College of Medicine Teen Health Clinic.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000/5 GELS FOR.
1 PREVENTION RESEARCH ADVOCACY COMMUNITY PREPAREDNESS IN HIV PREVENTION TRIALS AND USE OF EXISTING METHODOLOGIES MDP 301 trial in Mwanza, Tanzania Charles.
Presenters: Pauline Mingram & KG Ouye July 25, 2011 California State Library Public Access Technology Benchmarks Webinar.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
HOW ARE MDP PREPARING COMMUNITIES AT TRIAL SITES? MDP301.
Participating in an HIV vaccine trial By Jo Robinson, London, UK.
Clinical Trials and Research A Guide for Community Advisory Board Members Participant Manual.
Montreux, Switzerland, March 2007 New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications New Data on Male Circumcision and.
Working Synergistically: Two Possible Mechanisms.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
EFFECTIVE COMMUNICATIONS LOUISE BREAREY – PRINCIPAL ADVISOR WORKSAFE NZ.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.
International Partnership for Microbicides Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations.
Underage and Underserved
Phase III Microbicide Trials Update Dr. Lut Van Damme IAS Conference Sydney, Australia July 2007.
Peer Education Plus (PEP) Model; A Veritable Tool for achieving Behaviour Change. Experience from a Rural Community In Kaduna State, Nigeria AUTHORS: P.
Impact of level of researcher support on coital diary results and acceptability among women at high risk of HIV in the Microbicides Development Programme.
What is HIV research telling us about women’s sexuality? Exploring the construction of sexuality during the Phase III clinical trial of a microbicide gel.
Background Portsmouth Hospitals has a large maternity service with over 6000 births per annum There are 3 free standing midwifery led units (FMU), an alongside.
Primary Investigator: Prof. P Reddy Project Director: Ms S James
How informed is consent
On behalf of The MTN-020/ASPIRE Study Team
From Research to Rollout: Comparing oral PrEP and the dapivirine ring
The Irish Forum for Global Health, November 6th 2018 Sheila Garry
Presentation transcript:

Involving the Community in Randomised Microbicide Clinical Trials: Lessons from 6 MDP African Clinical Trial Sites So Far Richard I. Mutemwa CAR/S3RI

The Presentation What the Microbicide (MDP) trial is all about MDP Structure & Southampton Overall Trial Milestones  the community strand within it The Community Involvement Programme to date

What it is all about…. The MDP is a partnership set up to develop topical vaginal Microbicides for the prevention of HIV transmission Funded by DfID Co-ordinated jointly by MRC/CTU & Imperial College (St Mary’s Hosp.) Univ. of Southampton is a partner

What it is all about… II This is a Phase III trial Intention to test the efficacy of one candidate topical Microbicide gel: Pro 2000, in the prevention of HIV transmission thru heterosexual sex The Phase III trial is set up in 6 African sites: Ug (Masaka), Tz (Mwanza), Zm (Mazabuka), SA (Joburg, Durban, Mtubatuba)

MDP Structure & Soton MDP Working GroupsResponsible Coordinator Basic Science Laboratory ClinicalCTU Community Involvement (/Liaison) Southampton Social ScienceLSHTM Statistics DataCTU

Trial Milestones Site Preparation: contracts, advocacy, launch Feasibility Study: recruitment/retention/follow-up, tools design, community issues, HIV incidence/prevalence, sexual behaviour Pilot Study: tools pre-test, r-r-f with placebo product, community response to product Phase III (upcoming – April/May) COMMUNITY ROLE: intervention rather than data collection research

The Community Involvement Programme Implemented through CLOs Communication-centred  Liaison (CABs, CAGs, CACs)  Communication materials/media  Clinical Process: counsellors, reception  Service: services provided, quality of service Phased: entry – middle – exit

The CIP… II Pluralistic Approach to Community:  Public/Private (Non-Gov) Orgs  Leaders  Women of reprod. age  (Study participants)  Their partners/men  Others – social networks/opinion ‘consultants’ In-built dedicated monitoring system  Media: radio, suggestion boxes, meetings, counsellors, community reps, etc.  Community feedback: -ve & +ve

The CIP – Lessons What attracts women to the study?  ‘Familiarity’ of the CLO: enrolled women do help too  Clear, simple messages in local language: purpose, safety, other relevant clinical services, compensation  Continuous feedback loop, concerns addressed  Hope – in case the drug works for her!! What keeps women on the study?  Continuous feedback loop, concerns addressed – otherwise explained why not  Sustained hope  Consistency in messaging and sustained communication  Demonstrated, consistent confidentiality What makes women leave the study?  Rumour, stigma  Perceived lack of confidentiality  Partner hostility  Issues about compensation: did you consult?  Other priorities: education, work, household economy, migration, marriage, health, pregnancy, sexually inactive, etc.

The CIP – Lessons II Liaison : No ‘one shoe fits all’  Defining ‘community’ Representation : ‘Can I speak for myself, please’ Community ‘grows’ with the Trial : Entry, Mid-Phase, (Mature/Exit) Action Speaks Louder : little acts of compassion mean a lot more  ‘I feel I’m a good leader ‘cos I feel I represent a good project’ Social Marketing : Selling a clinical trial (research) Vs selling boreholes  ‘Will I have the drug free later?’  ‘Okay. But, then, why don’t you just give the product to everybody, we start using it, and then you see if it works!’ Pressure from Hope : presence of a product (probably) enhances compliance and minimizes loss to follow-up or dropping-out (feasibility vs. pilot)

The CIP – Some Challenges Partner/Men involvement : ‘Don’t tell my partner, please’ ‘High-Brow’ Benefits : ‘You brought the money and the product, we gave you our people’s sacrifices’ Compensation : ‘What? That is too little’ Terms/Notions :  ‘Random-ization? What’s that?’  ‘Placebo – do you mean it’s `fake`?’ “Trial Rush”:  ‘They said that they don’t care about us. Prove to us that you’re different’  ‘They gave us everything we asked for. We don’t understand why you are so reluctant’ Bottom-line : Is a common front for all trialists/researchers achievable?  How about possibility of overarching GLP guidelines (in the lines of GCP)?  for ethical & informed consent purposes